Introduction
============

Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality worldwide, and it is estimated that there are \~1.2 million newly diagnosed patients annually and \>600,000 patients succumbing to the disease globally ([@b1-mmr-16-04-3983]). In addition, CRC has been long prevalent in western populations, accounting for \~142,570 novel cases and 51,370 cancer-associated mortalities in the United States in 2010 ([@b2-mmr-16-04-3983]). CRC is characterized by late clinical presentation and a relatively rapid disease progression, which is the primary underlying reason for increased mortality and morbidity in patients suffering from this malignancy ([@b3-mmr-16-04-3983]). However, advances in treatment modalities, including surgery, radiation therapy and chemotherapy, have steadily improved the 5-year survival rate for CRC ([@b4-mmr-16-04-3983]). Etiologically, interactions of genetic and environmental factors are considered to be significant in the pathogenesis of CRC ([@b5-mmr-16-04-3983]). Certain epidemiological studies have reported that western dietary and behavior patterns, such as high fat, low fiber intake and deficiency of physical activity, which leads to obesity, insulin resistance and hypertension, were the predominant reason for increasing incidence of CRC, particularly in developing countries ([@b6-mmr-16-04-3983],[@b7-mmr-16-04-3983]). However, the associations between important adipokines, specifically between adiponectin (ADIPOQ) and its receptors (AdipoRs) and the risk of CRC have been demonstrated in a number of epidemiological studies ([@b8-mmr-16-04-3983],[@b9-mmr-16-04-3983]).

ADIPOQ, secreted exclusively by adipocytes, is a peptide hormone and insulin-sensitizing adipokine including two receptors, AdipoR1 (abundant in skeletal muscle cells) and AdipoR2 (predominantly in the liver cells) ([@b10-mmr-16-04-3983]). AdipoR2 is a protein, which in humans is encoded by the *AdipoR2* gene ([@b11-mmr-16-04-3983]). AdipoR2, possessing 7 transmembrane domains, mediates a number of metabolic processes, consisting of fatty acid oxidation and glucose uptake by ADIPOQ ([@b12-mmr-16-04-3983]). Notably, AdipoRs have been observed to be expressed in human malignant cells, such as CRC, breast and prostate cancer, and to mediate the anticancer activities of ADIPOQ in the cells ([@b13-mmr-16-04-3983]). Furthermore, certain single nucleotide polymorphisms (SNPs) in the *AdipoR2* gene, such as rs1342387, rs1063538, rs266729 and rs1862513, may be associated with CRC risk ([@b6-mmr-16-04-3983],[@b13-mmr-16-04-3983]--[@b15-mmr-16-04-3983]). In addition, rs10773989 and rs1044471 in the *AdipoR2* gene have been reported to be associated with various types of disease, such as type 2 diabetes, and prostate and gastric cancer ([@b16-mmr-16-04-3983]--[@b18-mmr-16-04-3983]). However, such associations between the SNPs in *AdipoR2* and CRC remain controversial ([@b19-mmr-16-04-3983],[@b20-mmr-16-04-3983]). In the current study, a case-control study was performed to systemically evaluate the associations of *AdipoR2* rs10773989 and rs1044471 SNPs and AdipoR2 protein expression levels with the risk of CRC.

Materials and methods
=====================

### Ethical approval

The present study was approved by the Ethics Committee of China-Japan Friendship Hospital (Beijing, China). All study participants provided written informed consent and the study conformed to the Declaration of Helsinki ([@b21-mmr-16-04-3983]).

### Study subjects

From April 2012 to May 2015, a total of 281 blood samples (3 ml each) were obtained from 281 hospitalized CRC patients from the China-Japan Friendship Hospital, who had been pathologically confirmed according to World Health Organization (WHO) guidelines. These 281 patients formed the case group (male, 165; female, 116; age range, 40--82 years; mean age, 60.40±10.40 years) ([@b22-mmr-16-04-3983]). The inclusion criteria were as follows: i) Patients with non-primary CRC; and ii) patients that had received preoperative chemotherapy or radiotherapy. During the corresponding period, a total of 325 blood samples (3 ml each) were collected from 325 healthy control subjects (male, 196; female, 129; age range, 44--91 years; mean age, 61.07±10.32 years), who had received a physical examination at the China-Japan Friendship Hospital, this group served as the control. The exclusion criteria were as follows: i) Healthy control subjects of a different ethnic background to the patients; ii) age differences between healthy control subjects and the patients \>3 years; iii) healthy control subjects in sibship with the patients; iv) healthy control subjects with tumors or diseases of the digestive system. The two groups were matched according to age (P\>0.05) and gender (P\>0.05). Following resection, the CRC tissue samples from all of the patients were dehydrated and embedded in paraffin for immunohistochemistry. In addition, 20 adjacent normal colon mucosa tissue samples (\>5 cm from the carcinoma) were randomly collected from the patients.

### DNA collection and genotyping

Peripheral blood (3 ml) was obtained in the morning from fasted CRC patients and healthy control subjects, respectively. The plasma was removed by centrifugation at 3,000 × g and room temperature for 15 min, 3 ml human erythrocyte lysate was added and mixed for 5 min to dissolve the erythrocyte and centrifuged at 10,000 × g for 30 sec for leukocyte sedimentation. After the addition of cell lysate, DNA was extracted using a DNA kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s instructions. An ultraviolet spectrophotometer (UV2600; Zhengzhou Nanbei Instrument Equipment Co., Ltd, China) was used to determine the DNA content and absorbance ratio (A; A~260~/A~280~), which was between 1.8 and 2.0. In the current study, rs10773989 and rs1044471 of the *AdipoR2* gene were selected to evaluate their association with the risk of CRC. The amplification primers for *AdipoR2* rs10773989 and rs1044471 were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA), and synthesized by Shanghai Sangon Biotechnology Co. Ltd. ([Table I](#tI-mmr-16-04-3983){ref-type="table"}).

The reaction conditions of the polymerase chain reaction (PCR) were as follows: 35 Cycles of pre-denaturation at 94°C for 2 min, denaturation at 94°C for 1 min, annealing at 52°C for 1 min, extension at 72°C for 1 min, followed by a final extension at 72°C for 5 min, then stored at 4°C. Genotyping was performed using denaturing high-performance liquid chromatography (DHPLC) in the condition of partial degeneration, with column temperature of 59.3°C and a flow rate of the mobile phase of 0.9 ml/min. The genotyping of rs10773989 was performed in two steps: i) The double-peak elution profile in DHPLC indicated heterozygotes (TC genotype) ([Fig. 1A](#f1-mmr-16-04-3983){ref-type="fig"}); and ii) the polymerase chain reaction (PCR) samples presenting a single-peak were mixed with an equal quantity of TT genotype sample confirmed by sequencing, and then genotyped by DHPLC, consequently, the single-peak elution profile indicated the TT genotype and the double-peak elution profile demonstrated the CC genotype ([Fig. 1B](#f1-mmr-16-04-3983){ref-type="fig"}). Mutation of the T and C allele was confirmed by sequencing, as presented in [Fig. 1C](#f1-mmr-16-04-3983){ref-type="fig"}. The genotyping of rs1044471 was also conducted in two steps: i) The double-peak elution profile in DHPLC indicated heterozygote (CT genotype; [Fig. 2A](#f2-mmr-16-04-3983){ref-type="fig"}); and ii) the PCR samples presenting a single-peak were mixed with an equal quantity of CC genotype sample, confirmed by sequencing, and then genotyped by DHPLC; consequently, the single-peak elution profile indicated the CC genotype and the double-peak elution profile suggested the TT genotype ([Fig. 2B](#f2-mmr-16-04-3983){ref-type="fig"}). Mutation of the T and C allele was confirmed by sequencing ([Fig. 2C](#f2-mmr-16-04-3983){ref-type="fig"}).

### Immunohistochemistry

All collected tissue samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sliced into 4-µm sections, and subjected to immunohistochemistry. The paraffin sections were baked, deparaffinized, dehydrated by successive soaking in dimethylbenzene, absolute ethyl alcohol, and 95 and 75% ethyl alcohol, and then washed in phosphate-buffered saline (PBS) three times. The tissue sections were immersed in antigen retrieval (AR) solution containing citric acid, and heated in a microwave oven for 12 min for AR. Subsequent to washing with PBS, H~2~O~2~ was added dropwise to block the peroxidase activity, and 50 µl endogenous biological blocker (solution A) was added dropwise and incubated at room temperature for 13 min to block tissue protein. Solution A was removed and 50 µl goat serum (solution B) was added and incubated at room temperature for 10 min, then the serum was removed. Primary antibody, rabbit anti-human AdipoR2 monoclonal antibodies (50 µl/section; cat. no. BS-0611R; Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China) at a dilution of 1:300 were diluted in Tris-buffered saline containing 2.5% bovine serum albumin. Biotinylated goat anti-rabbit IgG (1:200; cat. no. BA-1000; Vector Laboratories, Inc., Burlingame, CA, USA) served as the secondary antibody. All sections were stained with 3,3′-diaminobenzidine for 3--10 min and then re-stained with hematoxylin.

The results of immunohistochemistry were observed at a magnification of ×400 under an Olympus CKX41 inverted microscope, and analyzed using Image-Pro Plus v4.5 software (Media Cybernetics, Inc., Rockville, MD, USA) and the ZINO DH-CG 300 image analysis system (version 410; Beijing Daheng Image Vision Co. Ltd., Beijing, China). Eight high-power fields (HPFs) per section were randomly observed under the microscope (magnification, ×400) with 100 cells per HPF counted. The staining results were semi-quantitatively scored (the score of the percentage of stained cells × the score of staining intensity). The percentage of stained cells was scored as follows: 0 (negative) for \<5% stained cells; 1 (weak positive) for 6--20% stained cells; 2 (positive) for 21--50% stained cells; 3 (strong positive) for \>50% stained cells. The staining intensity was scored as: 0 (negative) for no intensity; 1 (weak positive) for light yellow; 2 (positive) for pale brown; and 3 (strong positive) for sepia. The staining results were divided into four grades as follows: i) 0, negative; ii) 1--3, weak positive; iii) 4--6, moderate positive; iv) 7--9, strong positive ([@b23-mmr-16-04-3983]).

### Statistical analysis

Statistical software SPSS 21.0 (IBM Corp., Armonk, NY, USA) was used to analyze data. Enumeration data were presented as percentage or rate. The χ^2^ test was applied for comparison of the genotype frequency differences between groups, and verified if the allele frequency was in Hardy-Weinberg equilibrium (HWE). Odds ratio (OR) and its 95% confidence interval (CI) was used to demonstrate the associations of various genotypes with CRC risk. The enumeration data was demonstrated as the mean ± standard deviation, and the differences of genotype frequency between groups were compared using the independent samples t-test. The haplotype frequency of rs10773989 and rs1044471 was analyzed using SHEsis analysis software, an online software platform that estimates haplotype frequencies (<http://analysis.bio-x.cn/SHEsisMain.htm>) ([@b24-mmr-16-04-3983]). The pathogenic factors of the patients were analyzed using multivariate non-conditioned logistic regression analysis and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline characteristics of CRC patients and healthy control subjects

As presented in [Table II](#tII-mmr-16-04-3983){ref-type="table"}, no significant differences in age, gender, smoking status, alcohol consumption, body mass index (BMI), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), or low-density lipoprotein cholesterol (LDL-C) were identified between the case group and the control group (P\>0.05). A statistically significant difference was observed in tumor history between the case and control groups (P\<0.05).

### Correlations of AdipoR2 gene polymorphisms with the risk of CRC

The genotype distribution of polymorphic loci in the control group was calculated to be in HWE (P\>0.05), indicating that the control subjects came from an equilibrium population and were therefore representative. As demonstrated in [Table III](#tIII-mmr-16-04-3983){ref-type="table"}, the frequencies of TC, CC, and TC + CC genotypes in *AdipoR2* rs10773989 were 38.79, 12.10 and 50.89%, respectively in CRC patients, and 46.46, 16.00 and 62.46%, respectively in the healthy control subjects, indicating significant differences from the TT genotype frequencies in *AdipoR2* rs10773989 (P\<0.05). The frequencies of T and C alleles in *AdipoR2* rs10773989 were 68.51 and 31.49%, respectively in CRC patients and 60.77 and 39.23%, respectively in healthy control subjects, which were significantly different (P\<0.05). In *AdipoR2* rs1044471, the frequencies of CT, TT, CT + TT genotypes in CRC patients were 30.60, 3.60 and 34.20%, respectively and were 38.15, 6.77 and 44.92%, respectively, in the healthy control subjects which were statistically different from the CC genotype frequency (P\<0.05). In addition, the frequencies of C and T alleles in *AdipoR2* rs10773989 were 81.14 and 18.86%, respectively in CRC patients and 74.15 and 25.85%, respectively in the healthy control subjects, and were significantly difference (P\<0.05).

### Correlations of AdipoR2 gene polymorphisms with clinicopathological features of CRC patients

According to the degree of tumor infiltration, CRC patients were divided into a serosal breakthrough group (n=219) and a non-serosal breakthrough group (n=62). In *AdipoR2* rs10773989, the frequencies of the TC + CC and TT genotypes were 33.33 and 66.67%, respectively in the non-serosal breakthrough group, and 55.71 and 44.29%, respectively in the serosal breakthrough group (χ^2^=9.219; P=0.002). No correlation was identified between the genotype distribution of *AdipoR2* rs10773989 and other clinicopathological features (P\>0.05; [Table IV](#tIV-mmr-16-04-3983){ref-type="table"}). According to the degree of differentiation, CRC patients were classified into poorly differentiated (n=126), moderately differentiated (n=93) and well-differentiated (n=62) groups. In *AdipoR2* rs1044471, the frequencies of CT + TT and CC genotypes were 39.68 and 60.32%, respectively in the poorly differentiated group, 37.63 and 62.37%, respectively in the moderately differentiated group, and 17.74 and 82.26%, respectively in the well-differentiated group, demonstrating statistical significance in the frequencies of CT + TT and CC genotypes among the poorly, moderately and well-differentiated groups (χ^2^=9.630; P=0.008). According to Dukes\' staging ([@b25-mmr-16-04-3983]), patients were separated into stage A (n=93), stage B (n=123) and stage C (n=65) groups. In *AdipoR2* rs1044471, the frequencies CT + TT and CC genotypes in the stage A group were 41.94 and 58.06%, respectively; 40.65 and 59.35%, respectively in the stage B group; and 20.93 and 79.07%, respectively in the stage C group, with significant differences among the stage A, B and C groups (χ^2^=7.470; P=0.024). No correlations were detected between the genotype distribution of *AdipoR2* rs1044471 and other clinicopathological features (P\>0.05; [Table V](#tV-mmr-16-04-3983){ref-type="table"}).

### Haplotype analysis of rs10773989 and rs1044471 polymorphisms in the AdipoR2 gene

The linkage disequilibrium and haplotype of *AdipoR2* rs10773989 and rs1044471 were analyzed using SHEsis analysis software. Linkage disequilibrium analysis revealed that the D\' value of rs10773989 and rs1044471 was 1, and r^2^ was 0.529, indicating linkage disequilibrium in rs10773989 and rs1044471. When the haplotype frequency was \>3%, three haplotypes were formed, including CC, CT and TC, among which, the CC haplotype was not significantly different between the CRC patients and healthy control subjects (P\>0.05). The CT haplotype was a protective factor for the healthy population (OR=0.667, 95% CI=0.507--0.878; P=0.004); individuals who carried the CT haplotype were considered to be low risk for CRC. The TC haplotype was positively correlated with the risk of CRC (OR=1.404, 95% CI=1.107--1.781; P=0.005) and the risk of CRC in individuals carrying the TC haplotype was increased ([Table VI](#tVI-mmr-16-04-3983){ref-type="table"}).

### Correlations of AdipoR2 protein expression levels with AdipoR2 gene polymorphisms and clinicopathological features of CRC patients

AdipoR2 protein was expressed in the CRC tissue samples and adjacent normal colon mucosa tissue samples, with positive staining predominantly localizing in the cytoplasm, showing light yellow, pale brown and sepia particles ([Fig. 3](#f3-mmr-16-04-3983){ref-type="fig"}). Correlation analysis of AdipoR2 protein expression levels in CRC tissue samples (n=281) with the genotype frequencies of rs10773989 and rs1044471, and clinicopathological features revealed that there were correlations of AdipoR2 protein expression with the degree of differentiation, Dukes\' staging, the degree of infiltration and lymph node metastasis (LNM) in CRC (P\<0.05). No correlations were identified between AdipoR2 protein expression levels and other clinicopathological features (P\>0.05; [Table VII](#tVII-mmr-16-04-3983){ref-type="table"}). In addition, the gene polymorphism of *AdipoR2* rs10773989 was statistically associated with the AdipoR2 protein expression level (P\<0.05).

### Non-conditional logistic regression analysis of risk factors for CRC

The multivariate non-conditioned logistic regression analysis was conducted with CRC as a dependent variable, and age, gender, smoking, alcohol consumption, tumor history, BMI, TG, HDL-C and LDL-C as independent variables. The results indicated that the TT genotype of *AdipoR2* rs10773989 (OR=1.434, 95% CI=1.087--1.893; P=0.011) and the CC genotype of *AdipoR2* rs1044471 (OR=1.610, 95% CI=1.190--2.177; P=0.002) were independent risk factors for CRC ([Table VIII](#tVIII-mmr-16-04-3983){ref-type="table"}).

Discussion
==========

This present study systematically evaluated the associations between two SNPs in the *AdipoR2* gene (rs10773989 and rs1044471), AdipoR2 protein expression levels and the risk of CRC. The present study indicated that the *AdipoR2* rs10773989 and rs1044471 polymorphisms may be correlated with the susceptibility to CRC, that the CT haplotype is a protective factor and that the TC haplotype is a risk factor in a healthy population. This indicated that carriers of the CT haplotype had a reduced CRC risk and carriers of the TC haplotype had an enhanced CRC risk. Furthermore, the TC haplotype and positive expression of the AdipoR2 protein may increase the risk of CRC.

ADIPOQ has been proposed as a biological link between obesity and various types of malignancy, such as CRC, through its actions mediated by binding and activating specific AdipoRs, including AdipoR1 and AdipoR2 ([@b26-mmr-16-04-3983]). In addition, AdipoRs have been identified to mediate the link between ADIPOQ and activation of adenosine monophosphate (AMP)-activated protein kinase, which causes ADIPOQ to exert antiproliferative effects in cancer cases ([@b27-mmr-16-04-3983]). The *AdipoR2* SNP rs10773989 may modulate the effects of ADIPOQ on cancer risk by regulating the protein expression of AdipoR2. It was confirmed in a previous study that SNP rs10773989 in the *AdipoR2* gene was statistically associated with AdipoR2 protein expression ([@b28-mmr-16-04-3983]). Therefore, it seems plausible that the SNPs in the *AdipoR2* gene may influence the protein expression of AdipoR2, and thereby repress the antiproliferative effects of ADIPOQ in cancer cases, which leads to increased risk of CRC. Furthermore, Byeon *et al* ([@b29-mmr-16-04-3983]) demonstrated that ADIPOQ levels are lower in patients with CRC when compared with healthy individuals; and its receptors, AdipoRs, expressed in adenocarcinoma and healthy colorectal tissue, may mediate its effects on cellular proliferation and apoptosis. Furthermore, in the present study, it was also revealed that the TT genotype of *AdipoR2* rs10773989 and the CC genotype of *AdipoR2* rs1044471 were independent risk factors for CRC. Similarly, allele C of rs10773989 and allele T of rs1044471 in the *AdipoR2* gene were reported to demonstrate significant associations with decreased risk of cardia cancers ([@b17-mmr-16-04-3983]). He *et al* ([@b14-mmr-16-04-3983]) demonstrated that the rs12733285 C/T genotype and carriage of the A allele of rs1342387 (A/G or A/A) in *AdipoR1* are protective factors for CRC, while rs266729 G/C and G allele of *ADIPOQ* are risk factors for CRC ([@b14-mmr-16-04-3983]). In a meta-analysis by Ou *et al* ([@b13-mmr-16-04-3983]), with a hospital-based case-control study of 341 cases and 727 control subjects, the associations between the common variants on *ADIPOQ* (rs266729, rs822395, rs2241766 and rs1501299) and *AdipoR1* (rs1342387 and rs12733285) and CRC susceptibility were evaluated, and it was demonstrated that variant rs1342387 on *AdipoR1* may be a novel CRC susceptibility factor. Ye *et al* ([@b27-mmr-16-04-3983]) systematically searched case-control studies published in February 2015 examining any *AdipoR1* polymorphisms and risk of any type of cancer, and suggested that the *AdipoR1* rs1342387 (G/A) polymorphism may be associated with cancer risk, particularly the risk of CRC in Asian individuals ([@b27-mmr-16-04-3983]). Al-Harithy and Al-Zahrani ([@b26-mmr-16-04-3983]) performed a case-control study on 60 CRC patients and 60 control subjects in a Saudi population, and revealed an enhanced risk of CRC that was associated with the 276T allele, and that the G allele at the T45 G polymorphism was associated with a lower CRC risk in *ADIPOQ* ([@b28-mmr-16-04-3983]).

In addition, the current study identified that the *AdipoR2* rs10773989 polymorphism was associated with the degree of tumor infiltration, while the *AdipoR2* rs1044471 polymorphism was associated with the degree of differentiation and Dukes\' staging in CRC. Furthermore, AdipoR2 protein expression was associated with the degree of differentiation, Dukes\' staging, the degree of tumor infiltration and LNM. These findings indicated that the SNPs of *AdipoR2*, rs10773989 and rs1044471, and AdipoR2 protein expression levels may be crucial in the progression of CRC. In addition, these findings may support the assumption that ADIPOQ suppresses tumor growth of CRC, as abundant AdipoR expression levels in CRC tissue may promote the anti-carcinogenic effect of ADIPOQ. By contrast, low AdipoR expression levels may facilitate CRC progression against the effects of ADIPOQ ([@b29-mmr-16-04-3983]). In line with the present findings, Gialamas *et al* ([@b26-mmr-16-04-3983]) reported that ADIPOQ levels and tissue expression of AdipoRs appeared to be associated with CRC risk and with a few clinicopathological features including advanced tumor grade, TNM stage and LNM ([@b26-mmr-16-04-3983]).

In conclusion, the findings of the present case-control study further exemplify the role of *AdipoR2* genetic polymorphisms (rs10773989 and rs1044471) and its protein expression in colorectal carcinogenesis and advancement. Large prospective studies are warranted to confirm these observations and further investigate the potential role of AdipoR2 as a therapeutic targ*et al*ong with their clinicopathological implications in CRC survival.
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![Denaturing high-performance liquid chromatography elution profiles of genotypes in rs10773989 and sequencing results of polymerase chain reaction products. (A) The double-peak elution profile indicated heterozygotes (TC genotype), and the single-peak elution profiles indicated the TT and CC genotype. (B) The single-peak elution profile indicated the TT genotype and the double-peak elution profile indicated the CC genotype. (C) A peak graph for sequencing of the T and C mutations.](MMR-16-04-3983-g00){#f1-mmr-16-04-3983}

![Denaturing high-performance liquid chromatography elution profiles of genotypes in rs1044471 and sequencing results of polymerase chain reaction products. (A) The double-peak elution profile indicated heterozygotes (CT genotype), and the single-peak elution profiles indicated the CC and TT genotype. (B) The single-peak elution profile indicated the CC genotype and the double-peak elution profile indicated the TT genotype. (C) A peak graph for sequencing of the C and T mutations.](MMR-16-04-3983-g01){#f2-mmr-16-04-3983}

![Immunohistochemistry results of adiponectin receptor 2 protein expression in the CRC tissue samples and adjacent normal colon mucosa tissue samples. (A) Weak positive staining and (B) positive staining in the CRC tissues. Negative control of (C) adjacent normal colon mucosa tissue samples and (D) CRC tissue samples (magnification, ×400). CRC, colorectal cancer.](MMR-16-04-3983-g02){#f3-mmr-16-04-3983}

###### 

Polymerase chain reaction primers for genotyping of adiponectin receptor 2 gene polymorphisms.

  Polymorphic locus   Primer sequence (5′-3′)   Location   Length (bp)   
  ------------------- ------------------------- ---------- ------------- -----
  rs10773989                                               intron        325
    Reverse           ATTCCAGACAAAGCGGAAGT                               
    Forward           CTGAAGACAATAAACCACAC                               
  rs1044471                                                intron        398
    Reverse           TTCCTAGACCAAGTACCTTAAG                             
    Forward           TCAGGCACTGCACCAGTTCAT                              

R, reverse; F, forward.

###### 

Baseline characteristics of patients with colorectal cancer (n=281) and healthy control subjects (n=325).

  Characteristic               Case          Control       *t*/χ^2^   P-value
  ---------------------------- ------------- ------------- ---------- ---------
  Age (years)                  60.40±10.40   61.07±10.32   0.794      0.427
  Gender, n (%)                                            0.158      0.691
    Male                       165 (58.72)   196 (60.31)              
    Female                     116 (41.28)   129 (39.69)              
  Smoking status, n (%)                                    0.293      0.588
    Yes                        79 (28.11)    85 (26.15)               
    No                         202 (71.89)   240 (73.85)              
  Alcohol consumption, n (%)                               0.553      0.457
    Yes                        55 (29.57)    56 (17.23)               
    No                         226 (80.43)   269 (82.77)              
  Tumor history, n (%)                                     5.454      0.019
    Yes                        30 (10.68)    18 (6.15)                
    No                         251 (89.32)   307 (93.85)              
  BMI (kg/m^2^)                23.05±1.64    22.85±1.68    1.478      0.140
  TC (mmol/l)                  5.10±0.88     4.98±0.72     1.846      0.065
  TG (mmol/l)                  1.84±0.96     1.96±1.18     1.359      0.174
  LDL-C (mmol/l)               2.58±1.07     2.44±1.09     1.590      0.112
  HDL-C (mmol/l)               1.34±0.36     1.32±0.71     0.427      0.669

Data are presented as the mean ± standard deviation or n number (percentage of total n number). BMI, body mass index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

###### 

Correlations of adiponectin receptor 2 genetic polymorphisms (rs10773989 and rs1044471) with the risk of colorectal cancer in the case (n=281) and control (n=325) groups.

  Genotype     Case group, n (%)   Control group, n (%)   Odds ratio (95% confidence interval)   χ^2^    P-value
  ------------ ------------------- ---------------------- -------------------------------------- ------- ---------
  rs10773989                                                                                             
    TT         138 (49.11)         122 (37.54)                                                           
    TC         109 (38.79)         151 (46.46)            1.567 (1.108--2.216)                   6.485   0.011
    CC           34 (12.10)          52 (16.00)           1.730 (1.053--2.842)                   4.741   0.029
    TC + CC    143 (50.89)         203 (62.46)            1.606 (1.161--2.221)                   8.238   0.004
    T          385 (68.51)         395 (60.77)                                                           
    C          177 (31.49)         255 (39.23)            1.404 (1.107--1.781)                   7.864   0.005
  rs1044471                                                                                              
    CC         185 (65.80)         179 (55.08)                                                           
    CT           86 (30.60)        124 (38.15)            1.190 (1.057--2.101)                   5.207   0.026
    TT           10 (3.60)           22 (6.77)            2.274 (1.047--4.937)                   5.509   0.034
    CT + TT      96 (34.20)        146 (44.92)            1.572 (1.131--2.185)                   7.273   0.007
    C          456 (81.14)         482 (74.15)                                                           
    T          106 (18.86)         168 (25.85)            1.499 (1.139--1.974)                   8.405   0.004

###### 

Correlation of adiponectin receptor 2 rs10773989 polymorphism with clinicopathological features of patients with colorectal cancer.

                                 Genotype                                                                             
  ------------------------------ ---------- ---- ----- ------------------------------------------------------- ------ -------------------------------------------------------
  Tumor diameter (cm)                                                                                                 
    \<5                            50       46   18    0.187                                                     64   0.155
    ≥5                             88       63   16                                                              79   
  Histological type                                                                                                   
    Papillary adenocarcinoma       43       36   10    0.999                                                     46   0.977
    Tubular adenocarcinoma         34       27     9                                                             36   
    Signet ring cell carcinoma     34       27     9                                                             36   
    Mucinous adenocarcinoma        27       19     6                                                             25   
  Degree of differentiation                                                                                           
    Poorly differentiated          63       45   18    0.557                                                     63   0.778
    Moderately differentiated      43       38   12                                                            50     
    Well-differentiated            32       26     4                                                             30   
  Dukes' staging                                                                                                      
    A                              46       35   12    0.126                                                     47   0.432
    B                              56       47   20                                                              67   
    C                              36       27     2                                                             29   
  Degree of tumor infiltration                                                                                        
    Non-serosal breakthrough       41       18     3   0.006^[a](#tfn3-mmr-16-04-3983){ref-type="table-fn"}^     21   0.002^[b](#tfn4-mmr-16-04-3983){ref-type="table-fn"}^
    Serosal breakthrough           97       91   31                                                            122    
  Lymph node metastasis                                                                                               
    No                           105        81   24    0.674                                                   105    0.608
    Yes                            33       28   10                                                              38   

P\<0.01, Non-serosal breakthrough vs. Serosal breakthrough (all genotypes combined)

P\<0.005, TT + TC vs. TT.

###### 

Correlation of the adiponectin receptor 2 rs1044471 polymorphism with clinicopathological features of patients with colorectal cancer.

                                 Genotype                                                                         
  ------------------------------ ---------- ---- --- ------------------------------------------------------- ---- -------------------------------------------------------
  Tumor diameter (cm)                                                                                             
    \<5                            75       37   2   0.374                                                   39   0.989
    ≥5                           110        49   8                                                           57   
  Histological type                                                                                               
    Papillary adenocarcinoma       59       24   6   0.501                                                   30   0.935
    Tubular adenocarcinoma         45       23   2                                                           25   
    Signet ring cell carcinoma     45       23   2                                                           25   
    Mucinous adenocarcinoma        36       16   0                                                           16   
  Degree of differentiation                                                                                       
    Poorly differentiated          76       42   8   0.007^[a](#tfn5-mmr-16-04-3983){ref-type="table-fn"}^   50   0.008^[b](#tfn6-mmr-16-04-3983){ref-type="table-fn"}^
    Moderately differentiated      58       34   1                                                           35   
    Well-differentiated            51       10   1                                                           11   
  Dukes\' staging                                                                                                 
    A                              54       37   2   0.040^[c](#tfn7-mmr-16-04-3983){ref-type="table-fn"}^   39   0.0240
    B                              73       43   7                                                           50   
    C                              58       17   1                                                           18   
  Degree of tumor infiltration                                                                                    
    Non-serosal breakthrough       46       14   2   0.281                                                   16   0.116
    Serosal breakthrough         139        72   8                                                           80   
  Lymph node metastasis                                                                                           
    No                           136        64   9   0.580                                                   73   0.645
    Yes                            49       22   1                                                           23   

P\<0.01 vs. all degree of differentiation types (all genotypes combined)

P\<0.01, CT + TT vs. TT

P\<0.05 vs. all Dukes\' staging types (all genotypes combined).

###### 

Comparison in haplotypes of rs10773989 and rs1044471 polymorphisms in the adiponectin receptor 2 gene between patients with colorectal cancer (case) and healthy control subjects.

  Haplotype   Case group (freq.)   Control group (freq.)   P-value   Odds ratio (95% confidence interval)
  ----------- -------------------- ----------------------- --------- --------------------------------------
  CC            42 (0.129)           36 (0.130)            0.880     1.026 (0.732--1.440)
  CT            84 (0.258)           53 (0.189)            0.004     1.499 (1.139--1.974)
  TC          199 (0.612)          192 (0.681)             0.008     0.726 (0.572--0.921)

###### 

Correlations of AdipoR2 protein expression with *AdipoR2* genetic polymorphisms (rs10773989 and rs1044471) and clinicopathological features of patients with colorectal cancer.

                                        AdipoR2 expression                 
  ------------------------------ ------ -------------------- ------------- -------
  rs10773989                                                               
    TT                           138    126 (91.30)          12 (8.69)     0.020
    TC + CC                      143    117 (81.82)          26 (18.18)    
  rs1044471                                                                
    CC                           185    157 (84.86)          28 (15.14)    0.273
    CT + TT                        96     86 (89.58)         10 (10.42)    
  Age (years)                                                              
    \<55                           83     73 (87.95)         10 (12.05)    0.640
    ≥55                          198    170 (85.86)          28 (14.14)    
  Gender                                                                   
    Male                         165    144 (87.27)          21 (12.73)    0.642
    Female                       116      99 (85.34)         17 (14.66)    
  Tumor diameter (cm)                                                      
    \<5                          114    100 (87.72)          14 (12.18)    0.615
    ≥5                           167    143 (85.63)          24 (14.37)    
  Histological type                                                        
    Papillary adenocarcinoma       89     74 (83.15)         15 (16.85)    0.665
    Tubular adenocarcinoma         70     61 (87.14)           9 (12.86)   
    Signet ring cell carcinoma     70     61 (87.14)           9 (12.86)   
    Mucinous adenocarcinoma        52     47 (90.38)           5 (9.62)    
  Degree of differentiation                                                
    Poor-differentiated          126    114 (90.48)          12 (9.52)     0.018
    Moderate-differentiated        93     82 (88.17)         11 (11.83)    
    Well-differentiated            62     47 (75.81)         15 (24.19)    
  Dukes staging                                                            
    A                              93     87 (93.55)           6 (6.45)    0.026
    B                            123    105 (85.37)          18 (14.63)    
    C                              65     51 (78.46)         14 (21.54)    
  Degree of tumor infiltration                                             
    Non-serosal breakthrough       62     48 (77.42)         14 (22.58)    0.018
    Serosal breakthrough         219    195 (89.04)          24 (10.96)    
  Lymph node metastasis                                                    
    No                           210    198 (94.29)          12 (5.71)     0.001
    Yes                            71     45 (63.38)         26 (36.62)    

AdipoR2, adiponectin receptor 2.

###### 

Non-conditional logistic regression analysis of risk factors in colorectal cancer.

                                                                             95% CI for EXP (β)   
  -------------------------- -------- ------- ---------- --- ------- ------- -------------------- -------
  Age                        0.008    0.008     1.017    1   0.313   1.008   0.992                1.025
  Gender                     0.114    0.180     0.400    1   0.527   1.121   0.787                1.596
  Alcohol consumption        −0.458   0.261     3.082    1   0.079   0.633   0.379                1.055
  Smoking condition          −0.444   0.274     2.621    1   0.105   0.642   0.375                1.098
  Tumor history              −0.580   0.325     3.182    1   0.074   0.560   0.296                1.059
  Body mass index            −0.050   0.052     0.919    1   0.338   0.952   0.860                1.053
  Triglyceride               0.119    0.080     2.224    1   0.136   1.126   0.963                1.316
  Low-density lipoprotein    −0.116   0.079     2.177    1   0.140   0.890   0.763                1.039
  High-density lipoprotein   −0.070   0.149     0.223    1   0.637   0.932   0.697                1.248
  rs10773989 TT                                 8.027    2   0.018                                
    rs10773989 TC            0.539    0.199     7.307    1   0.007   1.714   1.160                2.534
    rs10773989 CC            0.588    0.296     3.951    1   0.047   1.800   1.008                3.213
  rs1044471 CC                                  10.243   2   0.006                                
    rs1044471 CT             0.421    0.183     5.271    1   0.022   1.524   1.064                2.183
    rs1044471 TT             1.192    0.449     7.060    1   0.008   3.295   1.367                7.941

β, partial regression coefficient; Wald, Wald statistical test (maximum likelihood estimate); df, degrees of freedom; Exp(β), exponent function (β); 95% CI, 95% confidence interval.
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